Valeant Pharmaceuticals | StockChase
708
Valeant Pharmaceuticals (VRX-T)

Last Price Recorded: $25.3900 on 2017-12-15

ON STOCKCHASE SINCE Oct 2000

Consumer Products
708
Valeant Pharmaceuticals (VRX-T)

Last Price Recorded: $25.3900 on 2017-12-15

ON STOCKCHASE SINCE Oct 2000

Consumer Products

Valeant Pharmaceuticals


Signal Opinion Expert
COMMENT
Valeant Pharmaceuticals(VRX-T) 

December 14, 2017

He’s always very cautious with fallen angels. It almost takes a miracle to bring them back to life. The company has a huge debt. They still have some assets that are worthwhile, but are trying to work their way out of a very difficult situation. A long, hard road ahead before this company gets out of the woods.

Consumer Products

He’s always very cautious with fallen angels. It almost takes a miracle to bring them back to life. The company has a huge debt. They still have some assets that are worthwhile, but are trying to work their way out of a very difficult situation. A long, hard road ahead before this company gets out of the woods.

Consumer Products
David Cockfield

Managing Director, Northland Wealth Man...

PricePrice
$25.110
Owned Owned
Unknown

COMMENT
Valeant Pharmaceuticals(VRX-T) 

December 12, 2017

Has never been an owner of this. The stock had a nice bounce, but she still would not be a buyer. They've sold off some drugs, refinanced and pushed back some of the maturities on their debt, and thinks this is part of the reason why the stock has moved. It needs clarity on where they are going to get their future growth.

Consumer Products

Has never been an owner of this. The stock had a nice bounce, but she still would not be a buyer. They've sold off some drugs, refinanced and pushed back some of the maturities on their debt, and thinks this is part of the reason why the stock has moved. It needs clarity on where they are going to get their future growth.

Consumer Products
Christine Poole

CEO & Managing Director, GlobeInvest Capital ...

PricePrice
$28.180
Owned Owned
No

SPECULATIVE BUY
Valeant Pharmaceuticals(VRX-T) 

December 11, 2017

This is kicking around the $20 range. It has picked up recently, along with the entire pharmaceutical industry. Instead of being “extremely speculative” he would call it just “speculative” at this stage.

Consumer Products

This is kicking around the $20 range. It has picked up recently, along with the entire pharmaceutical industry. Instead of being “extremely speculative” he would call it just “speculative” at this stage.

Consumer Products
Bruce Murray

CEO & Chief Investment Officer, The Murray Wealth Gr...

PricePrice
$26.450
Owned Owned
No

COMMENT

The Dimension Fund (contrarian investors) has been buying to add to their position. When they buy into a company, that is a good sign for a lot of investors. This company has been a fascinating topic of conversation over the past few years. They were doing too many takeovers and taking on way too much debt. Still has a big debt load, but have been paying it off and he can see how this could be a good turnaround play. Because of their debt, there are still dangers out there.

Consumer Products

The Dimension Fund (contrarian investors) has been buying to add to their position. When they buy into a company, that is a good sign for a lot of investors. This company has been a fascinating topic of conversation over the past few years. They were doing too many takeovers and taking on way too much debt. Still has a big debt load, but have been paying it off and he can see how this could be a good turnaround play. Because of their debt, there are still dangers out there.

Consumer Products
Benj Gallander

President, Contra the Heard Inv...

PricePrice
$25.360
Owned Owned
Unknown

DON'T BUY

He is concerned about the debt they have carried and the legacy of it.  Management has done a good job of paying it down and refocusing the company, but a lot of people are looking at the price of 3 years ago and it is not getting back there.  He does not own any but is looking at JNJ-N and GILD-Q.

Consumer Products

He is concerned about the debt they have carried and the legacy of it.  Management has done a good job of paying it down and refocusing the company, but a lot of people are looking at the price of 3 years ago and it is not getting back there.  He does not own any but is looking at JNJ-N and GILD-Q.

Consumer Products
Lyle Stein

Sr. Portfolio & Managing Director, Vestcap Investment M...

PricePrice
$21.920
Owned Owned
No

WAIT

It topped mid-2015 and drifted. Does seems to be having some resistance around $22. If it breaks above 22-23$ and stays above for a few days, it might be worth buying. But buying here might reverse back down at the bottom of the trading pattern.

Consumer Products

It topped mid-2015 and drifted. Does seems to be having some resistance around $22. If it breaks above 22-23$ and stays above for a few days, it might be worth buying. But buying here might reverse back down at the bottom of the trading pattern.

Consumer Products
Keith Richards

Portfolio Manager, ValueTrend Wealth Ma...

PricePrice
$21.920
Owned Owned
Unknown

DON'T BUY
Valeant Pharmaceuticals(VRX-T) 

November 30, 2017

It has been better than over the last couple of years.  The valuation is cheap but there are a lot of headwinds with this company.  There is a heavy debt load.  Despite the long base it is building he is still staying on the sidelines.  You want to stay with the better quality names.  You want to stay away from most of that group.

Consumer Products

It has been better than over the last couple of years.  The valuation is cheap but there are a lot of headwinds with this company.  There is a heavy debt load.  Despite the long base it is building he is still staying on the sidelines.  You want to stay with the better quality names.  You want to stay away from most of that group.

Consumer Products
Don Lato

President, Padlock Investment M...

PricePrice
$21.730
Owned Owned
No

DON'T BUY
Valeant Pharmaceuticals(VRX-T) 

November 17, 2017

A really tough one, but chart shows it has a base at around the current price. The longer this goes at that price, the better it is for the stock. Healthcare is reasonable in this secular bull market. Until this gets above $25 it’s just too volatile. Anything between now and $25 might be better for a shorter-term trader.

Consumer Products

A really tough one, but chart shows it has a base at around the current price. The longer this goes at that price, the better it is for the stock. Healthcare is reasonable in this secular bull market. Until this gets above $25 it’s just too volatile. Anything between now and $25 might be better for a shorter-term trader.

Consumer Products
Hap (Robert) Sneddon FCSI

Chief Portfolio Manager & Founder, Castlemoore Inc....

PricePrice
$18.800
Owned Owned
Unknown

DON'T BUY

In 2015, this had a head and shoulders top and a neckline break. You don't want to buy a stock that is doing that. You need it to start to consolidate and break out. It is not doing that, so there is no reason to buy this.

Consumer Products

In 2015, this had a head and shoulders top and a neckline break. You don't want to buy a stock that is doing that. You need it to start to consolidate and break out. It is not doing that, so there is no reason to buy this.

Consumer Products
Keith Richards

Portfolio Manager, ValueTrend Wealth Ma...

PricePrice
$15.070
Owned Owned
Unknown

SELL

He used to love to say bad things about this company. It is going sideways and seems to be solving some of their overhanging debt problems. Expect you may have to see this stock go sideways for another couple of years before they sort out their game plan. Don’t go with fallen angels, move on to better places.

Consumer Products

He used to love to say bad things about this company. It is going sideways and seems to be solving some of their overhanging debt problems. Expect you may have to see this stock go sideways for another couple of years before they sort out their game plan. Don’t go with fallen angels, move on to better places.

Consumer Products
David Cockfield

Managing Director, Northland Wealth Man...

PricePrice
$14.640
Owned Owned
No

COMMENT
Valeant Pharmaceuticals(VRX-T) 

September 26, 2017

Thinks they have a definite a chance to survive. Have sales of about $9-$10 billion, and a huge debt load of around $40 billion. They have big problems, but the CEO says they are about where they want to be with the debt. Has all kinds of legal problems they have to deal with. Companies that do takeover after takeover and take on debt, generally get into trouble. Doesn’t feel it is cheap enough. If it got under $10, he might look at it.

Consumer Products

Thinks they have a definite a chance to survive. Have sales of about $9-$10 billion, and a huge debt load of around $40 billion. They have big problems, but the CEO says they are about where they want to be with the debt. Has all kinds of legal problems they have to deal with. Companies that do takeover after takeover and take on debt, generally get into trouble. Doesn’t feel it is cheap enough. If it got under $10, he might look at it.

Consumer Products
Benj Gallander

President, Contra the Heard Inv...

PricePrice
$17.420
Owned Owned
No

DON'T BUY
Valeant Pharmaceuticals(VRX-T) 

September 12, 2017

There is way too much debt on the balance sheet. The net debt to EBITDA is about 7X, very, very high. New management has come in, made some asset sales and paid off some debt that was coming due. The next tranche of debt is not due until 2020. However, there is very little visibility in terms of their products going forward. They are going to experience more genetic competition and pricing pressure in their dermatology division. It is hard to see how they are going to generate the necessary cash to start their debt repayments down the road.

Consumer Products

There is way too much debt on the balance sheet. The net debt to EBITDA is about 7X, very, very high. New management has come in, made some asset sales and paid off some debt that was coming due. The next tranche of debt is not due until 2020. However, there is very little visibility in terms of their products going forward. They are going to experience more genetic competition and pricing pressure in their dermatology division. It is hard to see how they are going to generate the necessary cash to start their debt repayments down the road.

Consumer Products
Christine Poole

CEO & Managing Director, GlobeInvest Capital ...

PricePrice
$17.600
Owned Owned
No

WATCH

There are concerns overall with prices of drugs in the US.  Healthcare costs for US citizens continue to go up.  Earnings are expected to go down 31% this year.  At some point investors will probably warm up to this stock.

Consumer Products

There are concerns overall with prices of drugs in the US.  Healthcare costs for US citizens continue to go up.  Earnings are expected to go down 31% this year.  At some point investors will probably warm up to this stock.

Consumer Products
Robert McWhirter

President, Selective Asset Mana...

PricePrice
$17.620
Owned Owned
Unknown

DON'T BUY

He missed the Up and the Down.  It is stabilizing and now becoming a regular company again.  It is too unstable still for him.  He owns a Danish Pharma and thereby misses the volatility of this one.

Consumer Products

He missed the Up and the Down.  It is stabilizing and now becoming a regular company again.  It is too unstable still for him.  He owns a Danish Pharma and thereby misses the volatility of this one.

Consumer Products
Bruce Campbell (1)

President, Campbell and Lee Inv...

PricePrice
$18.180
Owned Owned
No

WATCH

He said he would not buy it on the way up because they were doing so many takeovers.  They took on a lot of debt to do it and now they are paying the piper.  The CEO says the selloff is done, but the financial statements say there is a lot of debt out there.  He would consider buying it during tax loss season.

Consumer Products

He said he would not buy it on the way up because they were doing so many takeovers.  They took on a lot of debt to do it and now they are paying the piper.  The CEO says the selloff is done, but the financial statements say there is a lot of debt out there.  He would consider buying it during tax loss season.

Consumer Products
Benj Gallander

President, Contra the Heard Inv...

PricePrice
$17.510
Owned Owned
Unknown

Showing 1 to 15 of 707 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.

Successfully Saved Company